Perrigo and Catalent announce FDA approval of Perrigo's AB-rated generic version of ProAir HFA

Perrigo

24 February 2020 - Perrigo and its partner, Catalent Pharma Solutions, today announced that the U.S. FDA has approved Perrigo's abbreviated new drug application for generic albuterol sulphate inhalation aerosol, the first AB-rated generic version of ProAir HFA. 

Perrigo is launching a limited quantity of generic albuterol sulphate inhalation aerosol and, in collaboration with its development and manufacturing partner Catalent, is ramping up production to meet future demand.

Read Perrigo press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , US , Generic medicine